Ochoge M, Futa AC, Umesi A, Affleck L, et al. Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial. Lancet 2024 Feb 22:S0140-6736(23)02844-1. doi: 10.1016/S0140-6736(23)02844.
PMID: 38402887